





Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease

Reinoud Gosens¹, Pieter S. Hiemstra ¹², Ian M. Adcock ³³, Ken R. Bracke⁴, Robert P. Dickson ^{5,6}, Philip M. Hansbro^{7,8}, Susanne Krauss-Etschmann^{9,10}, Hermelijn H. Smits ¹¹, Frank R.M. Stassen¹² and Sabine Bartel ^{9,13}

Affiliations: ¹University of Groningen, Dept of Molecular Pharmacology, GRIAC Research Institute, Groningen, The Netherlands. ²Dept of Pulmonology, Leiden University Medical Center (LUMC), Leiden, The Netherlands. ³Airways Disease, National Heart and Lung Institute, Imperial College London, London, UK. ⁴Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. ⁵Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. ⁶Michigan Center for Integrative Research in Critical Care, Ann Arbor, MI, USA. ⁷Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and the University of Newcastle, Newcastle, Australia. ⁸Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, Sydney, Australia. ⁹Early Life Origins of Chronic Lung Disease, Research Center Borstel, Leibniz Lung Center, Airway Research Center North, Member of the German Center for Lung Research (DZL), Borstel, Germany. ¹⁰Institute for Experimental Medicine, Christian-Albrechts-Universitaet zu Kiel, Kiel, Germany. ¹¹Dept of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. ¹²Dept of Medical Microbiology, NUTRIM – School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands. ¹³University of Groningen, University Medical Center Groningen, Dept of Pathology and Medical Biology, GRIAC Research Institute, Groningen, The Netherlands.

Correspondence: Sabine Bartel, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. E-mail: s.r.bartel@umcg.nl

@ERSpublications

The reciprocal interaction between microbes and host in the lung is increasingly recognised as an important determinant of health. The complexity of this cross-talk needs to be taken into account when studying diseases and developing future new therapies. https://bit.ly/2VKYUfT

Cite this article as: Gosens R, Hiemstra PS, Adcock IM, *et al.* Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease. *Eur Respir J* 2020; 56: 1902320 [https://doi.org/10.1183/13993003.02320-2019].

This single-page version can be shared freely online.

ABSTRACT Chronic respiratory diseases are highly prevalent worldwide and will continue to rise in the foreseeable future. Despite intensive efforts over recent decades, the development of novel and effective therapeutic approaches has been slow. However, there is new and increasing evidence that communities of micro-organisms in our body, the human microbiome, are crucially involved in the development and progression of chronic respiratory diseases. Understanding the detailed mechanisms underlying this cross-talk between host and microbiota is critical for development of microbiome- or host-targeted therapeutics and prevention strategies. Here we review and discuss the most recent knowledge on the continuous reciprocal interaction between the host and microbiome- in health and respiratory disease. Furthermore, we highlight promising developments in microbiome-based therapies and discuss the need to employ more holistic approaches of restoring both the pulmonary niche and the microbial community.

Copyright @ERS 2020. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.